Pharmacokinetic Profile of A New Diclofenac Prodrug without Gastroulcerogenic Effect

Drug Metabolism Letters

Volumn 6, Issue 4, 2013, Pages 235-241

  de Campos, Michel Leandro ^a   Baldan Cimatti, Helen Mariana ^a   Davanço, Marcelo Gomes ^a   Nogueira, Marco Antônio Ferraz ^a   Padilha, Elias Carvalho ^a   Candido, Caroline Damico ^a   dos Santos, Jean Leandro ^a   Peccinini, Rosângela Gonçalves ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

1 (2,6 dichlorophenyl)indolin 2 one; Bioanalytical method; Diclofenac prodrug; Preclinical pharmacokinetic profile

Indexed keywords

[1 (2,6 DICHLOROPHENYL)INDOLIN 2 ONE]; DICLOFENAC; DICLOFENAC DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; MALE; NONHUMAN; PHARMACEUTICAL EQUIVALENCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT;

ANIMALS; DICLOFENAC; INDOLES; MALE; PRODRUGS; RATS; RATS, WISTAR; STOMACH ULCER;

EID: 84884239265     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872312811206040002     Document Type: Article

References (21)

1. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDs. Cardiovasc. J. Afr., 2008, 19, 102-107.
2. Brooks, P.; Kubler, P. Etoricoxib for arthritis and pain management. Ther. Clin. Risk Manag., 2006, 2, 45-57.
3. Fendrick, A. M.; Greenberg, B. P. A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis. Osteopath Med Prim Care, 2009, 3, 1-7.
4. Ng, A. W. K.; Lukic, T. Pritchard PH, Wasan KM. Development of Novel Water-Soluble Phytostanol Analogs: Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4): Preclinical Pharmacology, Pharmacokinetics and Toxicology. Card. Drug Rev., 2003, 21, 151-168.
5. Takemoto, J. K.; Reynolds, J. K.; Remsberg, C. M.; Vega-Villa, K. R.; Davies, N. M.; Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib. Clin. Pharmacokinet., 2008, 47, 703-720.
6. Aithal, G. P.; Day, C. P. Nonsteroidal Anti-Inflammatory Drug-Induced Hepatotoxicity. Clin. Liver Dis., 2007, 11, 563-575.
7. Chung, M. C.; Santos, J. L.; Oliveira, E. V.; Blau, L.; Menegon, R. F.; Peccinini, R. G. Synthesis, ex vivo and in vivo Hydrolysis Study of na Indoline Derivative Designed as na Anti-Inflammatory with Reduced Gastric Ulceration Properties. Molecules 2009, 14, 3187-3197.
8. Masimirembwa, C. M.; Bredberg, U.; Andersson, T. B. Metabolic Stability for Drug Discovery and Development: Pharmacokinetic and Biochemical Challenges. Clin. Pharmacokinet, 1996, 42, 515-528.
9. Singh, S. S.; Demircan, B.; Karagoz, Y. Preclinical Pharmacokinetics: An Approach Towards Safer and Efficacious Drugs. Curr. Drug Metab., 2006, 7, 165-182.
10. Resolution-n. 899, of May 29, 2003. Guia para validação de métodos analíticos e bioanalíticos. Agência Nacional de Vigilância Sanitária (ANVISA). http://www.anvisa.gov.br/legis/resol/2003/re/ 899_03re.htm (Acessed June 07, 2011).
11. GUIDANCE FOR INDUSTRY: BIOANALYTICAL METHOD VALIDATION. US Department of Health and Human Services, Food and Drug Administration (FDA). http://www.fda.gov/ downloads/Drugs/./Guidances/ucm070107.pdf (Acessed June 07, 2011).
12. rd ed.; CRC Press: New York, 2009.
13. De Paula, P.M.; Castania, J.A.; Bonagamba, L.G.; Salgado, H.C.; Machado, B.H. Hemodynamic responses to electrical stimulation of the aortic depressor nerve in awake rats. Am. J. Physiol., 1999, 277, 31-38.
14. Mactutus, C.F.; Herman, A.S.; Booze, R.M. Chronic intravenous model for studies of drug (Ab)use in the pregnant and/or grouphoused rat: an initial study with cocaine. Neurotoxicol. Teratol., 1994, 16, 183-191.
15. Roupe, K.A.; Yáñez, J.A.; Teng, X.W.; Davies, N.M. Pharmacokinetics of selected stilbenes: rhapontigenin, piceatannol and pinosylvin in rats. J. Pharm. Pharmacol., 2006, 58, 1443-1450.
16. Lisciotto, C.A.; DeBold, J.F. Intravenous administration of progesterone and the onset of receptivity in female hamsters. Physiol. Behav., 1991, 49, 679-683.
17. Kim, Y. C.; Oh, E. Y.; Kim, S. H.; Myung, G. L. Pharmacokinetics of Diclofenac in Rat Model of Diabetes Mellitus Induced by Alloxan or Steptozotocin. Biopharm. Drug Dispos., 2006, 27, 85-92.
18. García-López, P.; Salas, R. Bioavailability of diclofenac after intramuscular administration to rats with experimental spinal cord injury. J. Pharmacol. Toxicol. Methods, 1999, 42, 99-101.
19. Toutain, P. L.; Bousquet-Mélou, A. Plasma Clearance. J. Vet. Pharmacol. Ther., 2004, 27, 415-425.
20. Quevedo, M. A.; Briñón, M. C. In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. Antiviral Res., 2009, 83, 103-111.
21. Pang, K. S.; Morris, M. E.; Sun, H. Formed and preformed metabolites: facts and comparisons. J. Pharm. Pharmacol., 2008, 60, 1247-1275.